March 3, 2010
Exhibit (a)(4)
March 3, 2010
Dear Shareholders:
We are pleased to inform you that, on January 31, 2010,
Global Med Technologies, Inc. (“Global Med”)
entered into an Agreement and Plan of Merger (the
“Merger Agreement”) with Haemonetics
Corporation, a Massachusetts corporation
(“Haemonetics”), and Atlas Acquisition Corp., a
Colorado corporation and wholly-owned subsidiary of Haemonetics
(the “Purchaser”).
Under the terms of the Merger Agreement and subject to the
conditions set forth in the Purchaser’s Offer to Purchase
(including the minimum tender condition) and the related
materials previously mailed to you on February 19, 2010 by
the Purchaser, the Purchaser has commenced a cash tender offer
(the “Offer”) to purchase (1) all of the
outstanding shares of our common stock, par value $0.01 per
share (“Global Med Common Stock”) at a price of
$1.22 per share in cash, net to the holders of Global Med’s
Common Stock, and (2) all of the outstanding shares of our
preferred stock, par value $0.01 per share (“Global Med
Preferred Stock” and together with Global Med Common
Stock, each a “Share,” and collectively, the
“Shares”), at a price of $1,694.44 per share in
cash (which equates to $1.22 per share on a converted to Global
Med Common Stock basis), net to the holders of Global Med
Preferred Stock. Enclosed is the
Schedule 14D-9
that was prepared by Global Med and contains the recommendation
of your board of directors with respect to the Offer and the
Merger.
Unless subsequently extended in accordance with its terms, the
Offer is scheduled to expire at 12:00 midnight, Boston,
Massachusetts time, on March 18, 2010, after which time, if
all conditions to the Offer have been satisfied or waived, the
Purchaser will accept for payment all Shares validly tendered
pursuant to the Offer and not properly withdrawn. If the Offer
is successfully consummated, the Purchaser will merge with and
into Global Med on the terms and subject to the conditions set
forth in the Merger Agreement (the “Merger”),
and each Share that is outstanding and that has not been
accepted for purchase pursuant to the Offer (other than any
Shares held by a shareholder who has properly perfected his, her
or its dissenters’ rights under applicable Colorado law)
will be automatically cancelled and converted into the right to
receive, in cash and without interest and subject to any
required withholding taxes, $1.22 per share of Global Med Common
Stock or $1,694.44 per share of Global Med Preferred Stock (or,
if higher amounts are paid in the Offer, such higher amounts).
The terms of the Merger Agreement were negotiated by a special
committee of independent directors of Global Med. Your board
of directors (including all of the members of the special
committee): (i) has declared the Merger Agreement and all
of the transactions contemplated thereby, including the Offer
and the Merger, advisable and in the best interests of Global
Med and its shareholders; (ii) has approved the Offer and
Merger in accordance with the Colorado Business Corporation Act
and the Colorado Corporations and Associations Act;
(iii) has adopted the Merger Agreement; (iv) has
approved and authorized the execution and delivery of the Merger
Agreement; and (v) recommends that the shareholders of
Global Med accept the Offer, tender their Shares in the Offer
and, if required by applicable law, adopt and approve the Merger
Agreement and approve the Merger.
In arriving at its recommendation, your board of directors gave
careful consideration to a number of factors that are described
in the enclosed
Schedule 14D-9.
The Purchaser previously mailed to you a copy of its Offer to
Purchase and related materials (including letters of transmittal
for use in tendering your Shares to the Purchaser in the Offer).
Those documents set forth the terms and conditions of the Offer
and provide
instructions as to how to tender your Shares. We urge you to
read carefully all of the materials delivered to you.
Thank you for your continued support of Global Med.
Very truly yours,
Xxxxxxx X. Xxxxx, M.D.
Chairman of the Board and Chief Executive
Officer
